Adding GnRH analogue to chemotherapy reduced early menopause in patients with ...
Temporarily suppressing ovarian function using the gonadotropin-releasing hormone analogue triptorelin reduced the rate of chemotherapy-induced early menopause among premenopausal women with breast cancer, according to researchers in Italy.
Chemotherapy is associated with at least a 40% incidence of long-term amenorrhea , with the most marked effect seen with regimens containing a high cumulative dose of cyclophosphamide, according to background data supplied in the study. Previous preclinical data from phase 2 studies have demonstrated that the use of a gonadotropin-releasing hormone (GnRH) analogue during chemotherapy reduced ovarian toxicity and protected the ovaries of 67% and 96% of women with breast cancer, respectively.
Prevention of Menopause Induced by Chemotherapy: A Study in Early Breast Cancer Patients–Gruppo Italiano Mammella 6 (PROMISE-GIM6) — a randomized, open-label, phase 3 superiority study — included 281 premenopausal women with stage I to stage III breast cancer enrolled at 16 sites in Italy between October 2003 and January 2008. All patients were eligible for adjuvant or neoadjuvant chemotherapy.
Patients were randomly assigned to chemotherapy alone (n=133) or chemotherapy plus 3.75 mg triptorelin (n=148) administered intramuscularly at least 1 week before chemotherapy, then every 4 weeks for the duration of chemotherapy. The primary endpoint was incidence of early menopause, defined as discontinuation of menstrual activity and postmenopausal levels of follicle-stimulating hormone and estradiol, 12 months after the last cycle of chemotherapy.
There was an absolute difference of –17% in the rate of early menopause (95% CI, –26 to –7.9) among those in the chemotherapy-alone group (rate of 25.9%) vs. the chemotherapy plus triptorelin group (rate of 8.9%). The median time to menses continuation was 6.7 months among women assigned to chemotherapy plus triptorelin, but menses resumption was not achieved among women in the chemotherapy-alone group. The OR for chemotherapy-related early menopause was 0.28 (95% CI, 0.14-0.59).
Gonadotropin Releasing Hormone - News
Temporarily suppressing ovarian function using the gonadotropin-releasing hormone analogue triptorelin reduced the rate of chemotherapy-induced early menopause among premenopausal women with breast cancer, according to researchers in Italy.
In a phase 3 study, triptorelin, a gonadotropin-releasing hormone agonist (GnRH), was administered to suppress ovarian function during chemotherapy in the hope of protecting women 18 to 45 years of age from ovarian failure, say the authors,
The rate of early menopause 12 months after last chemotherapy cycle in patients randomised to chemotherapy plus the gonadotropin-releasing hormone (GnRH) analogue triptorelin (n=148) was 8.9% compared to 25.9% in those given chemotherapy-alone (n=133),
induced ovarian suppression in some young patients with stage I-III breast cancer with hormones secreted by the pituitary gland, known as gonadotropin-releasing hormone or GnRH analogue triptorelin, before breast cancer surgery and/or chemotherapy.
Before discussing the attributes and benefits of burdock, readers are cautioned to regard the pituitary and its involvement in various hormonal functions including its role in the regulation of gonadotropin-releasing hormone (GnRH), luteinizing hormone
Gonadotropin-Releasing Hormone Pulse Sensitivity of Follicle-Stimulating Hormone-beta Gene Is Mediated by... 
Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin ...: Effect of the Gonadotropin-Releasing Horm... 
Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early M… 
Gonadotropin Releasing Hormone Analogs: Applications in Gynecology: 
Gonadotropin Releasing Hormone Analogs: Applications in Gynecology: Gonadotropin Releasing Hormone - Bookshelf
Gonadotropin-releasing hormone, molecules and receptors
This volume summarizes the evolution and physiology of GnRH molecules and receptors, and provides insight as to how social behavior influences cellular and ...Gonadotropin Releasing Hormone, its possible usage in the management of dairy heifers and postpartum cows
Gonadotropin-Releasing Hormone
Gonadotropin-releasing hormone, structure and function in cartilaginous fish and radiation in the vertebrata
Basic medical endocrinology
Gonadotropin Releasing Hormone (GnRH) GnRH was the next hypophysiotropic hormone to be isolated and characterized. Hypothalamic control over secretion of ...Helpful Information Directory
Gonadotropin-releasing hormone - Wikipedia, the free encyclopedia
Gonadotropin-releasing hormone (GnRH), also known as Luteinizing-hormone-releasing ... The biology of gonadotropin hormone-releasing hormone: role in the ...
gonadotropin-releasing hormone: Definition from Answers.com
gonadotropin-releasing hormone n. ( Abbr. GnRH ) A hormone produced by the hypothalamus that signals the anterior pituitary gland to begin secreting
Gonadotropin-Releasing Hormone Deficiency in Adults
Gonadotropin-releasing hormone (GnRH) is a neurohormone central to initiation of the reproductive hormone cascade.
Gonadotropin releasing hormone - WrongDiagnosis.com
Gonadotropin releasing hormone information including symptoms, causes, diseases, symptoms, treatments, and other medical and health issues.
Gonadotropin-releasing hormone receptor - Wikipedia, the free ...
The gonadotropin-releasing hormone receptor (GNRHR), also known as the ... ed. "The human gonadotropin releasing hormone type I receptor is a functional ...